Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMETEK, Inc. (AME) vs Invesco Ltd. (IVZ) Price & Performance

AMETEK, Inc.Trade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

AMETEK, Inc. vs Invesco Ltd. — how do they compare? AMETEK, Inc. trades at $259.52 (market cap $58.76B), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: AMETEK, Inc. is far larger — about 4.2× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.74%). Which is the better fit depends on your goals.

AMEIVZ
Market Cap
$58.76B$13.85B
Sector
IndustrialsFinancials
52-Week High
$256.30$32.01
52-Week Low
$179.28$20.67
Enterprise Value
$60.30B$24.01B
Dividend Yield
0.53%2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMETEK, Inc.

AME trades at $258.62, up 2.27% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The company reported record Q2 results and raised full-year guidance, supported by robust revenue growth and a 20.04% net income margin. Analysts maintain a consensus buy rating with a $281.86 price target, reflecting optimism about its 3D printing and electronics testing segments.

The outlook is positive given consistent earnings beats and upward guidance, but risks include high valuation multiples (P/E 37.47) and exposure to macroeconomic volatility. Institutional sentiment remains strong, with no sell ratings among 30 analysts, though the stock's proximity to resistance at $261 warrants caution for near-term entries.

Invesco Ltd.

Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.

The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMETEK, Inc.

Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.

Read more on AME

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ